{"source_content":"www.swsc.com.cn2020年1-12月血制品批签发：Q4国产人白持续下滑西南证券研究发展中心2021年1月分析师：杜向阳执业证号：S1250520030002电话：021-68416017邮箱：duxy@swsc.com.cn分品种来看：人血白蛋白（规格换算/10g）：2020年1-12月，人血白蛋白批签发总量为5989万瓶(+13%)，其中国产人血白蛋白批签发总量为2107万瓶(-1%)，占比为35%；进口人血白蛋白批签发总量为3882万瓶(+23%)，占比为65%。免疫球蛋白：2020年1-12月，静丙（规格换算/2.5g）批签发总量为1238万瓶，同比增长5%；其中，2020年12月静丙批签发量为79万瓶，同比下降8%；其他品种如狂免（规格换算/200IU）1186万瓶(-3%)、破免（规格换算/250IU）602万瓶(-5%)、免疫球蛋白（规格换算/150mg）470万瓶(+79%)。凝血因子类：凝血因子VIII（规格换算/200IU）199万瓶(+7%)、PCC（规格换算/200IU）157万瓶(+51%)、纤原（规格换算/0.5g）125万瓶(+41%)。分公司来看：华兰生物：人白获批255万瓶(+4%)，破免获批152万瓶(+5%)，凝血因子VIII获批56万瓶(-13%)，PCC获批64万瓶(+25%)。双林生物：人白获批115万瓶(+17%)，静丙获批67万瓶(+40%)，狂免获批134万瓶(+11%)。卫光生物：人白获批119万瓶(+22%)，狂免获批203万瓶(+96%)，破免获批11万瓶(-56%)，免疫球蛋白获批27万瓶(-45%)。天坛生物：人白获批434万瓶(+0%)，静丙获批289万瓶(+2%)，狂免获批67万瓶(-40%)，破免获批96万瓶(-31%)，乙免获批33万瓶(-40%)。博雅生物：人白获批135万瓶(+47%)，静丙获批64万瓶(+12%)，狂免获批82万瓶(+25%)，纤原获批24万瓶(-13%)。投资建议：由于2020年疫情影响采浆量，预计2021年血制品供给收紧趋势有望显现，重点推荐双林生物（000403.SZ）、卫光生物（002880.SZ）、天坛生物（600161.SH）、华兰生物（002007.SZ），建议关注博雅生物（300294.SZ）。2020年1-12月血制品批签发：Q4国产人白持续下滑风险提示：政策变化风险；企业产品质量风险；新品种研发不及预期。数据来源：wind，西南证券整理1数据来源：中检院，西南证券整理，截至2020.12.05分品种批签发数据汇总2020年1-12月血制品各品种批签发情况2血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-12月2020年1-12月2019年12月2020年12月2020年11月2020年12月人血白蛋白（规格换算/10g）进口总计3161.373882.260.23353.25369.905%438.42369.90-16%进口占比60%65%/63%71%/75%71%/国产总计2123.512107.19-1%208.63151.32-27%145.67151.324%国产占比40%35%/37%29%/25%29%/总计5284.885989.4513%561.88521.22-7%584.09521.22-11%免疫球蛋白静注人免疫球蛋白（规格换算/2.5g）总计1183.731237.845%85.8278.62-8%83.2978.62-6%狂犬病免疫球蛋白（规格换算/200IU）总计1219.671185.62-3%113.94118.654%81.19118.6546%破伤风免疫球蛋白（规格换算/250IU）合计633.36601.74-5%79.7220.76-74%75.4920.76-72%免疫球蛋白（规格换算/150mg）合计262.12470.0579%91.62128.3940%51.55128.39149%乙型肝炎免疫球蛋白（规格换算/100IU）合计206.15217.976%25.5533.0329%9.0133.03267%冻干静注人免疫球蛋白（规格换算/1.0g）总计63.68106.0967%9.724.86-50%9.524.86-49%静注乙型肝炎免疫球蛋白（规格换算/2000IU）四川远大2.472.7813%0.730.00/0.000.00/凝血因子类凝血因子VIII（规格换算/200IU）总计186.07198.927%10.0013.9339%5.5913.93149%凝血酶原复合物（规格换算/200IU）合计103.83157.0551%8.9015.5274%19.6315.52-21%纤维蛋白原（规格换算/0.5g）总计89.19125.4841%5.846.9319%25.076.9319%1.人血白蛋白：1-12月同比增长13%，进口占比六成以上，2020Q4同比+0.3%，12月同比-7%。2.静丙：1-12月同比增长5%，前五家公司市场份额达72%，2020Q4同比-15%，12月同比-8%。3.狂犬病免疫球蛋白：1-12月同比下降3%，前三家公司份额达48%，2020Q4同比+8%，12月同比+4%。4.破伤风免疫球蛋白：1-12月同比下降5%，前三家公司份额达65%，2020Q4同比+37%，12月同比-74%。5.免疫球蛋白：1-12月同比增长79%，博晖创新、博雅生物份额近三成，2020Q4同比+55%，12月同比+40%。6.乙肝免疫球蛋白：1-12月同比增长6%，前两家份额近五成，2020Q4同比+4%，12月同比29%。7.凝血因子Ⅷ：1-12月同比增长达7%，上海莱士、泰邦生物份额近60%，2020Q4同比-40%，12月同比39%。8.凝血酶原复合物：1-12月同比增长51%，泰邦生物占比超五成市场份额，2020Q4同比+171%，12月同比+74%。9.纤维蛋白原：1-12月同比增长达41%，上海莱士、泰邦生物份额达56%，2020Q4同比+128%，12月同比+19%。2020年1-12月各品种批签发摘要32020年1-12月血制品公司批签发情况4华兰生物:1-12月共9个品种获批。人白获批255万瓶(+4%)，静丙获批131.14万瓶(-9%)，破免获批152万瓶(+5%)，凝血因子VIII获批56万瓶(-13%)，PCC获批64万瓶(+25%)。双林生物:1-12月共4个品种获批。人白获批115万瓶(+17%)，静丙获批67万瓶(+40%)，狂免获批134万瓶(+11%)。卫光生物:1-12月共7个品种获批。人白获批119万瓶(+22%)，静丙获批72.55万瓶(+28%)，狂免获批182万瓶(+76%)，破免获批11万瓶(-56%)，免疫球蛋白获批27万瓶(-45%)。天坛生物:1-12月共8个品种获批。人白获批434万瓶(+0%)，静丙获批301万瓶(+2%)，狂免获批67万瓶(-40%)，破免获批96万瓶(-31%)，乙免获批33万瓶(-40%)。上海莱士:1-12月共9个品种获批。人白获批305万瓶(+15%)，静丙获批197万瓶(+43%)，冻干静丙获批46万瓶(+78%)，凝血因子VIII获批60万瓶(+68%)，纤原获批47万瓶(+320%)。博雅生物:1-12月共7个品种获批，人白获批135万瓶(+47%)，静丙获批64万瓶(+12%)，狂免获批82万瓶(+25%)，纤原获批24万瓶(-13%)。博晖创新:1-12月共5个品种获批。人白获批54万瓶(+26%)，狂免获批21万瓶(-18%)，免疫球蛋白获批77万瓶(+289%)，冻干静丙获批53万瓶(+6%)。泰邦生物:1-12月共9个品种获批。人白获批309万瓶(-22%)，静丙获批171.19万瓶(-15%)，PCC获批85万瓶(+65%)。1.人血白蛋白：同比增长13%，进口占比六成以上2007-2020M12人血白蛋白批签发总量数据来源：药智网，中检院，西南证券整理从批签发来看，2007-2020年人血白蛋白批签发复合年均增长率(CAGR)为+21.61%。2019年，国内人血白蛋白批签发量为5285万瓶(+11%)，其中国产批签发为2120万瓶(+13%)，占比40%，进口批签发为3165万瓶(+11%)，占比60%。（规格换算/10g）2020年1-12月，人血白蛋白批签发总量为5989万瓶(+13%)，其中国产人血白蛋白批签发总量为2107万瓶(-1%)，占比为35%；进口人血白蛋白批签发总量为3882万瓶(+23%)，占比为65%。2020Q4人血白蛋白批签发总量为1435万瓶(+0.3%)，其中国产人血白蛋白批签发量为439万瓶(-12%)，占比31%；进口人血白蛋白批签发量为996万瓶(+7%)，占比69%。2020年12月人血白蛋白批签发总量为521万瓶(-7%)，其中国产人血白蛋白批签发量为151万瓶(-27%)，占比29%；进口人血白蛋白批签发量为370万瓶(+5%)，占比71%。2007-2020M12进口与国产人血白蛋白批签发量占比5进口与国产人血白蛋白分季度批签发占比1.人血白蛋白：同比增长13%，进口占比六成以上2020年1-12月进口人血白蛋白批签发份额为65%，批签发总量前4位的进口厂商分别为杰特贝林(CSL)获批1316万瓶(-8%)、奥克特珐玛(Octa-pharma)获批950万瓶(+147%)、基立福(Grifols)获批816万瓶(+31%)、百特(Baxter)获批739万瓶(+7%)。国产人血白蛋白批签发份额为35%，前4位的厂商是分别是天坛生物获批434万瓶(+0%)、泰邦生物获批309万瓶(-22%)、上海莱士获批305万瓶(+15%)和华兰生物获批255万瓶(+4%)。2020年12月，人血白蛋白批签发同比下降7%，进口同比上升5%，国产同比下降27%。其中进口人血白蛋白12月份共5家企业获批签发；国产人血白蛋白12月份共13家企业获批签发。数据来源：药智网，中检院，西南证券整理2020M1-M12人血白蛋白批签发占比62007-2020M12进口人血白蛋白批签发数量进口人血白蛋白批签发量2007年-2020年CAGR(年均复合增长率)为+32.88%，2020年1-12月进口人血白蛋白批签发量为3882万瓶，同比增长23%。2020年12月进口人血白蛋白批签发量为370万瓶，同比上升5%。2020年1-12月进口人血白蛋白批签发主要集中在几家大型的血制品企业，批签发总量前4位的进口厂商分别为杰特贝林(CSL)获批1316万瓶(-8%)、奥克特珐玛(Octa-pharma)获批950万瓶(+147%)、基立福(Grifols)获批816万瓶(+31%)、百特(Baxter)获批739万瓶(+7%)，合计占比高达98%，市场集中度高。2020M1-M12进口人血白蛋白批签发占比1.1进口人血白蛋白：2020年1-12月批签发量同比增长23%数据来源：药智网，中检院，西南证券整理71.1进口人血白蛋白：2020年1-12月批签发量同比增长23%2007-2020M12进口人血白蛋白外国厂商批签发量占比人血白蛋白过去三年分季度外国厂商批签发量占比数据来源：药智网，中检院，西南证券整理82020年12月，奥克特珐玛(Octa-pharma)获批124万瓶(+774%)、杰特贝林(CSL)获批68万瓶(-51%)、基立福(Grifols)获批34万瓶(-74%)、百特(Baxter)获批39万瓶(-33%)。1.1进口人血白蛋白：2020年1-12月批签发量同比增长23%2020M1-M12进口人血白蛋白批签发数量对比数据来源：药智网，中检院，西南证券整理9血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-12月2020年1-12月2019年12月2020年12月2020年11月2020年12月进口人血白蛋白（规格换算/10g）Biotest0.0019.90/0.000.00/0.000.00/CSL1423.131316.05-8%137.1667.57-51%111.0267.57-39%奥克特珐玛383.83949.55147%25.66224.37774%158.34224.3742%百特693.72739.167%58.4439.12-33%44.3539.12-12%基立福622.49815.5931%132.0034.03-74%121.5134.03-72%绿十字株式会社/韩国38.2042.0110%0.004.82/3.204.8251%进口总计3161.373882.2623%353.25369.905%438.42369.90-16%进口占比60%65%/63%71%/75%71%/国产人血白蛋白批签发量2007-2020年CAGR为+16%，近五年保持10%以上稳定增长。2020年1-12月国产批签发量为2107万瓶，同比下降1%。其中2020年12月国产人血白蛋白批签发量为151万瓶，同比下降27%。2020年1-2月，共14家国产企业获批人血白蛋白。其中，批签发占比最高的分别是天坛生物获批434万瓶(+0%)、泰邦生物获批309万瓶(-22%)、上海莱士获批305万瓶(+15%)和华兰生物获批255万瓶(+4%)。1.2国产人血白蛋白：2020年1-12月批签发量小幅下降2007-2020M12国产人血白蛋白批签发数量2020M1-M12国产人血白蛋白批签发占比数据来源：药智网，中检院，西南证券整理10人血白蛋白过去三年分季度国产企业批签发量占比1.2国产人血白蛋白：2020年1-12月批签发量小幅下降2007-2020M12人血白蛋白国产企业批签发量占比数据来源：药智网，中检院，西南证券整理112020年12月，上海莱士24万瓶(+8%)、华兰生物21万瓶(-35%)、天坛生物16万瓶(-26%)。2007年-2020年12月，国产人血白蛋白批签发份额比较分散，批签发量较高的企业主要是天坛生物（占国产4%~24%）、泰邦生物（占国产5%~17%）、上海莱士（占国产5%~14%）与华兰生物（占国产4%~12%）。1.2国产人血白蛋白：2020年1-12月批签发量小幅下降2020M1-M12国产人血白蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理12血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-12月2020年1-12月2019年12月2020年12月2020年11月2020年12月国产人血白蛋白（规格换算/10g）博晖创新42.7353.8426%6.842.85-58%4.262.85-33%博雅生物91.64134.7647%27.103.20-88%13.783.20-77%华兰生物244.95255.294%32.1720.91-35%24.5920.91-15%绿十字20.5420.942%1.642.9278%0.002.92/南岳生物81.5959.73-27%0.008.65/3.468.65150%派斯菲科92.8851.33-45%15.302.21-86%0.002.21/山西康宝77.5154.82-29%5.6511.1898%6.8011.1864%上海莱士264.53305.4015%22.5024.338%28.9724.33-16%双林生物98.87115.4417%10.2317.0166%18.0917.01-6%四川远大163.52184.5713%17.1719.3713%13.9519.3739%泰邦生物395.06308.67-22%36.178.44-77%0.008.44/天坛生物431.97433.620%21.8116.10-26%17.6416.10-9%卫光生物97.48119.2722%12.0514.1617%14.1214.160%武汉中原瑞德3.380.00/0.000.00/0.000.00/新疆德源生物14.539.52-35%0.000.00/0.000.00/中国新兴2.330.00/0.000.00/0.000.00/国产总计2123.512107.19-1%208.63151.32-27%145.67151.324%国产占比40%35%/37%29%/25%29%/总计5284.885989.4513%561.88521.22-7%584.09521.22-11%2.静丙：同比增长5%，前五家公司市场份额达72%2007-2020M12静丙批签发数量数据来源：药智网，中检院，西南证券整理静丙批签发量2007-2020年CAGR为+16%。2020年1-12月，静丙批签发总量为1238万瓶，同比增长5%；其中，2020Q4静丙批签发量为234.15万瓶，同比下降15%；2020年12月静丙批签发量为79万瓶，同比下降8%。2020年1-12月，总共12家国产企业获批静丙。其中，批签发量最高的分别是天坛生物301万瓶(份额24%)、上海莱士197万瓶(份额16%)、泰邦生物171万瓶(份额14%)、华兰生物131万瓶(份额11%)、四川远大95万瓶(份额8%)。（规格换算/1.0g）2020M1-M12静丙批签发占比13数据来源：药智网，中检院，西南证券整理2.静丙：同比增长5%，前五家公司市场份额达72%静丙过去三年分季度批签发份额占比2007-2020M12静丙批签发份额占比142007年-2020年12月，批签发量较高的企业有地坛生物（份额1%~27%）、泰邦生物（份额9%~22%）、上海莱士（份额9%~19%）和华兰生物（份额10%~20%）。2020年12月，静丙批签发量同比下降8%，其中批签发份额前4位分别为上海莱士12万瓶(份额26%)，同比下降30%、天坛生物12万瓶(份额16%)，同比上升11%、华兰生物14万瓶(份额13%)，同比上升12%、泰邦生物6万瓶(份额12%)，同比上升83%，合计份额达67%。数据来源：药智网，中检院，西南证券整理2.静丙：同比增长5%，前五家公司市场份额达72%2020M1-M12静丙批签发数量及同比增速15血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-12月2020年1-12月2019年12月2020年12月2020年11月2020年12月静注人免疫球蛋白（规格换算/2.5g）博雅生物56.7763.5012%5.105.345%2.575.34108%华兰生物144.75131.14-9%12.4013.8612%10.5613.8631%杰特贝林1.740.00/0.000.00/0.000.00/绿十字(中国)8.488.21-3%0.870.00/0.000.00/南岳生物37.8248.7329%0.000.00/3.850.00/派斯菲科43.8642.22-4%5.000.00/0.000.00/山西康宝49.1740.25-18%6.310.00/0.000.00/上海莱士137.82196.9743%17.0211.98-30%20.7211.98-42%双林生物47.8267.0340%5.5010.8397%3.4110.83217%四川远大104.6595.40-9%11.369.09-20%9.129.090%泰邦生物200.55171.19-15%3.476.3383%13.096.33-52%天坛生物293.77300.652%10.8212.0211%12.8612.02-6%卫光生物56.5372.5528%7.969.1615%7.109.1629%总计1183.731237.845%85.8278.62-8%83.2978.62-6%3.狂犬病免疫球蛋白：同比小幅下降，前三家公司份额达48%数据来源：中检院，西南证券整理2008-2020M12狂犬病免疫球蛋白批签发数量2020M1-M12狂犬病免疫球蛋白批签发占比16狂犬病免疫球蛋白批签发量2008-2020复合年均增长率(CAGR)为+19%，2016-2020年批签发增长迅速。2020年1-12月狂犬病免疫球蛋白批签发总量为1186万瓶，同比下降3%；2020Q4狂犬病免疫球蛋白批签发量为330万瓶，同比上升8%；2020年12月狂犬病免疫球蛋白批签发量为119万瓶，同比上升4%。（规格换算/200IU）2020年1-12月共有10家公司获批狂犬病免疫球蛋白，批签发量前3位公司分别为四川远大获批193万瓶(份额16%)，同比下降1%；卫光生物获批203万瓶(份额17%)，同比增长96%；泰邦生物获批162万瓶(份额14%)，同比下降13%，合计份额为48%。狂犬病免疫球蛋白过去三年分季度批签发份额占比2008-2020M12狂犬病免疫球蛋白批签发占比数据来源：药智网，中检院，西南证券整理173.狂犬病免疫球蛋白：同比小幅下降，前三家公司份额达48%近三年狂犬病免疫球蛋白批签发份额较为分散。2008-2020年12月，批签发量较高的分别为双林生物(占总量8%~62%)、四川远大(占总量9%~32%)、泰邦生物(占总量2%~30%)。2020年12月，共5家公司获狂犬病免疫球蛋白批签发，其中华兰生物获批42万瓶(份额35%)，同比增长404%；泰邦生物获批14万瓶(份额12%)，同比下降40%；四川远大获批9万瓶(份额7%)，同比下降能3%，双林生物获批33万瓶(份额28%)，去年同期无批签发。2020M1-M12狂犬病免疫球蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理183.狂犬病免疫球蛋白：同比小幅下降，前三家公司份额达48%血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-12月2020年1-12月2019年12月2020年12月2020年11月2020年12月狂犬病免疫球蛋白（规格换算/200IU）博晖创新26.1521.37-18%0.000.00/0.000.00/博雅生物65.5782.0425%13.240.00/11.900.00/华兰生物125.86130.564%8.3542.02404%12.3642.02240%南岳生物59.5457.11-4%0.000.00/21.800.00/上海莱士225.53135.51-40%15.630.00/20.810.00/双林生物120.97134.1211%0.0032.60/0.0032.60/四川远大193.68192.54-1%19.329.11-53%14.319.11-36%泰邦生物186.66162.19-13%23.9914.35-40%0.0014.35/天坛生物111.8966.74-40%33.410.00/0.000.00/卫光生物103.83203.4396%0.0020.57/0.0020.57/总计1219.671185.62-3%113.94118.654%81.19118.6546%4.破伤风免疫球蛋白：同比下降5%，前三家公司份额达63%2008-2020M12破伤风免疫球蛋白批签发数量数据来源：药智网，中检院，西南证券整理2020M1-M12破伤风免疫球蛋白批签发占比19破伤风免疫球蛋白批签发量2008-2020年复合年均增长率(CAGR)为+10.77%。过去十年破伤风免疫球蛋白批发量波动较大，整体呈增长态势。2020年1-12月，破伤风免疫球蛋白批签发总量为602万瓶，同比下降5%；2020Q4，破伤风免疫球蛋白批签发量为190万瓶，同比上升37%；2020年12月份，破伤风免疫球蛋白批签发量为21万瓶，同比下降74%。（规格换算/250IU）2020年1-12月，共8家企业获得批签发，华兰生物获批152万瓶(份额25%)，同比增长5%；泰邦生物获批136万瓶(份额23%)，同比下降9%；四川远大获批85万瓶(份额14%)，同比上升4%；天坛生物获批96万瓶(份额16%)，同比下降31%，合计份额为80%。破伤风免疫球蛋白过去三年分季度批签发份额占比2008-2020M12破伤风免疫球蛋白批签发份额占比数据来源：药智网，中检院，西南证券整理204.破伤风免疫球蛋白：同比下降5%，前三家公司份额达63%破伤风免疫球蛋白批签发量2008-2020年复合年均增长率(CAGR)为+10.77%。过去十年破伤风免疫球蛋白批发量波动较大，整体呈增长态势。2020年1-12月，破伤风免疫球蛋白批签发总量为602万瓶，同比下降5%；2020年12月份，破伤风免疫球蛋白批签发量为21万瓶，同比下降74%。（规格换算/250IU）2020年1-12月，共8家企业获得批签发，华兰生物获批152万瓶(份额25%)，同比增长5%；泰邦生物获批136万瓶(份额23%)，同比下降9%；四川远大获批85万瓶(份额14%)，同比上升4%；天坛生物获批96万瓶(份额16%)，同比下降31%，合计份额为80%。4.破伤风免疫球蛋白：同比下降5%，前三家公司份额达63%2020M1-M12破伤风免疫球蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理21血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-11月2020年1-11月2019年11月2020年11月2020年10月2020年11月破伤风免疫球蛋白（规格换算/250IU）博晖创新5.251.98-62%0.000.00/0.000.00/华兰生物145.47152.185%34.417.05-80%11.987.05-41%南岳生物4.400.00/0.000.00/0.000.00/上海莱士39.6246.3917%0.000.00/0.000.00/双林生物42.3272.5271%6.6213.71107%10.5413.7130%四川远大81.7684.714%4.940.00/8.330.00/泰邦生物149.74136.38-9%15.660.00/23.290.00/天坛生物138.8796.21-31%13.290.00/21.350.00/卫光生物25.9411.38-56%4.800.00/0.000.00/合计633.36601.74-5%79.7220.76-74%75.4920.76-72%5.免疫球蛋白：同比增长94%，博晖创新、博雅生物份额超四成2008-2020M12年免疫球蛋白批签发数量数据来源：中检院，西南证券整理免疫球蛋白批签发量2008-2020复合增长率(CAGR)为+9.86%，免疫球蛋白批签发量具有较强的周期性，大约3-5年为一个周期。2020年1-12月，免疫球蛋白批签发量为470万瓶，同比增长79%；2020Q4，免疫球蛋白批签发量为230万瓶，同比上升55%；2020年12月，免疫球蛋白批签发量为128万瓶，同比上升40%。（规格换算/150mg）2020年1-12月，博晖创新获批77万瓶(份额16%)，同比增长289%；博雅生物51万瓶(份额11%)，同比增长202%；新疆德源生物获批160万瓶(份额34%)，去年同期无批签发；卫光生物获批27万瓶(份额6%)，同比下降45%；上海莱士获批27万瓶(份额6%)，同比下降6%；派斯菲科获批22万瓶(份额4%)，去年同期无批签发。2020M1-M12免疫球蛋白批签发占比225.免疫球蛋白：同比增长94%，博晖创新、博雅生物份额超四成免疫球蛋白过去三年分季度批签发份额占比2008-2020M12免疫球蛋白批签发份额占比数据来源：药智网，中检院，西南证券整理23免疫球蛋白临床使用风险较高，每年批签发量波动较大，企业市场份额变化明显。2017年-2020年11月，批签发量较高的企业分别为博晖创新(占总量7%~52%)、卫光生物(占总量4%~19%)、华兰生物(占总量3%~37%)。2020年1-12月，总共9家国企获批免疫球蛋白，其中，批签发量最高的分别是博晖创新获批77万瓶(份额16%)，同比增长289%；博雅生物51万瓶(份额11%)，同比增长202%；新疆德源生物获批160万瓶(份额34%)，去年同期无批签发；卫光生物获批27万瓶(份额6%)，同比下降45%；上海莱士获批27万瓶(份额6%)，同比下降6%；派斯菲科获批22万瓶(份额4%)，去年同期无批签发。5.免疫球蛋白：同比增长94%，博晖创新、博雅生物份额超四成2020M1-M12人免疫球蛋白批签发数量及同比增速数据来源：药智网，中检院，西南证券整理24血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-12月2020年1-12月2019年12月2020年12月2020年11月2020年12月免疫球蛋白（规格换算/150mg）博晖创新19.8977.29289%0.006.80/0.006.80/博雅生物16.7550.52202%0.000.00/10.610.00/华兰生物33.0236.6311%5.8312.34112%5.8812.34110%派斯菲科0.0021.98/0.000.00/0.000.00/上海莱士28.6627.04-6%0.000.00/0.000.00/四川远大10.140.00/0.000.00/0.000.00/泰邦生物18.119.28-49%9.500.00/0.000.00/天坛生物86.5360.12-31%76.290.00/30.240.00/卫光生物49.0227.06-45%0.000.00/0.000.00/新疆德源生物0.00160.12/0.00109.25/4.82109.252166%合计262.12470.0579%91.62128.3940%51.55128.39149%6.乙肝免疫球蛋白：同比增长6%，前两家份额近五成2008-2020M12乙肝免疫球蛋白批签发情况数据来源：中检院，西南证券整理2020M1-M12乙肝免疫球蛋白批签发情况(万瓶)25乙肝免疫球蛋白2007-2020复合增长率(CAGR)为-1.07%。2020年1-12月，乙肝免疫球蛋白批签发总量为218万瓶，同比上升6%；2020Q4，乙肝免疫球蛋白批签发量为83万瓶，同比上升4%；2020年12月份，乙肝免疫球蛋白批签发量为33万瓶，同比上升29%。2020年1-12月，共7家公司获批签发，分别为四川远大获批57万瓶(份额26%)，同比增长134%；华兰生物获批42万瓶(份额19%)，同比增长65%；天坛生物33万瓶(份额15%)，同比下降40%；泰邦生物获批26万瓶(份额12%)，同比上升5%；博雅生物获批7万瓶(份额4%)，去年同期无批签发。(规格换算/100IU)乙肝免疫球蛋白过去三年分季度批签发份额占比2008-2020M12乙肝免疫球蛋白批签发份额占比6.乙肝免疫球蛋白：同比增长6%，前两家份额近五成过去十年乙肝免疫球蛋白批签发量呈缓慢下降趋势。2008年以来，乙肝免疫球蛋白批签发份额波动较大，总体上批签发量较高的企业为华兰生物(占总量7%~29%)、天坛生物(占总量7%~46%)、四川远大(占总量9%~29%)。2020年12月份，乙肝免疫球蛋白获批33万瓶，同比上升29%，批签发数量均来自于上海莱士。数据来源：药智网，中检院，西南证券整理266.乙肝免疫球蛋白：同比增长6%，前两家份额近五成2020M1-M12乙肝免疫球蛋白批签发数量及同比增速27血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-11月2020年1-11月2019年11月2020年11月2020年10月2020年11月乙型肝炎免疫球蛋白（规格换算/100IU）博雅生物0.007.35/0.000.00/0.000.00/华兰生物25.5942.1165%0.000.00/0.000.00/南岳生物25.9116.63-36%0.000.00/0.000.00/上海莱士50.3935.22-30%10.5320.2893%0.0020.28/四川远大24.5457.46134%0.0012.75/0.0012.75/泰邦生物25.0226.295%0.000.00/9.010.00/天坛生物54.7032.91-40%15.020.00/0.000.00/合计206.15217.976%25.5533.0329%9.0133.03267%7.凝血因子Ⅷ：同比增长达7%，上海莱士、泰邦生物份额近60%2008-2020M12凝血因子Ⅷ批签发数量凝血因子VIII行业2008-2020年CAGR为-2%，自2011年以来批签发量稳步增长。2020年1-12月，凝血因子Ⅷ批签发总量为199万瓶，同比增长7%；2020Q4，凝血因子Ⅷ批签发量为33万瓶，同比下降-40%；2020年12月，凝血因子Ⅷ批签发量为14万瓶，同比上升39%。（规格换算/200IU）2020年1-12月共有5家公司获批凝血因子Ⅷ，其中上海莱士获批66万瓶(份额33%)，同比增长67%；泰邦生物获批48万瓶(份额24%)，同比下降12%；华兰生物获批56万瓶(份额28%)，同比下降13%；绿十字获批29万瓶(份额15%)，同比增长5%。2020M1-M12凝血因子VIII批签发占比数据来源：药智网，中检院，西南证券整理287.凝血因子Ⅷ：同比增长达7%，上海莱士、泰邦生物份额近60%2008-2020M12凝血因子Ⅷ批签发份额占比凝血因子Ⅷ过去三年分季度批签发份额占比2008-2020年12月，批签发量最高的企业分别是华兰生物(占总量24%~61%)、上海莱士(占总量9%~44%)、绿十字(占总量7%~46%)。2020年12月，凝血因子Ⅷ批签发量为14万瓶，同比上升39%。华兰生物获批9万瓶，同比上升1217%；上海莱士获批5万瓶，同比上升55%。数据来源：药智网，中检院，西南证券整理297.凝血因子Ⅷ：同比增长达7%，上海莱士、泰邦生物份额近60%2020M1-M12凝血因子VIII批签发数量及同比增速数据来源：药智网，中检院，西南证券整理30血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-11月2020年1-11月2019年11月2020年11月2020年10月2020年11月凝血因子VIII（规格换算/200IU）华兰生物64.9256.28-13%0.678.851217%4.468.8599%绿十字27.5228.955%2.220.00/0.000.00/上海莱士39.2365.5367%3.295.0855%1.135.08350%泰邦生物54.4047.79-12%3.820.00/0.000.00/天坛生物0.000.37/0.000.00/0.000.00/总计186.07198.927%10.0013.9339%5.5913.93149%8.凝血酶原复合物：同比增长51%，泰邦生物占比超五成市场份额2008-2020M12凝血酶原复合物批签发数量2020M1-M12凝血酶原复合物批签发占比数据来源：药智网，中检院，西南证券整理31凝血酶原复合物批签发2008-2020年CAGR为+30.06%。2008-2006年快速增长，2017年受两票制影响，行业整体处于去库存周期，批签发相对平稳。2020年1-12月批签发量有明显增长。2020年1-12月，凝血酶原复合物批签发总量为157万瓶，同比增长51%；2020Q4，凝血酶原复合物批签发量为66万瓶，同比上升171%；2020年12月，凝血酶原复合物批签发量为16万瓶，同比上升74%。（规格换算/200IU）2020年1-12月,凝血酶原复合物批签发市场主要3家公司占据，分别为泰邦生物85万瓶(份额54%)和华兰生物64万瓶(份额41%)，南岳生物8万瓶(份额5%),泰邦生物的市场份额持续稳定。8.凝血酶原复合物：同比增长51%，泰邦生物占比超五成市场份额2008-2020M12凝血酶原复合物批签发份额占比凝血酶原复合物过去三年分季度批签发份额占比数据来源：药智网，中检院，西南证券整理322008-2014年间，华兰生物的凝血酶原复合物批签发份额占70%以上。2015年以后，国内凝血酶原复合物批签发企业以泰邦生物与华兰生物为主。上海新兴事件过后，国内凝血酶原复合物生产企业只有泰邦生物与华兰生物两家。2015-2020年12月，华兰生物批签发份额为36%~75%，泰邦生物批签发份额为12%~64%。2020年12月，凝血酶原复合物批签发量为16万瓶，其中泰邦生物获批3万瓶，同期无批签发数据，华兰生物获批12万瓶(36%)。8.凝血酶原复合物：同比增长51%，泰邦生物占比超五成市场份额数据来源：药智网，中检院，西南证券整理332020M1-M12凝血酶原复合物批签发数量及同比增速血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-11月2020年1-11月2019年11月2020年11月2020年10月2020年11月凝血酶原复合物（规格换算/200IU）华兰生物51.2164.1525%8.9012.1136%6.0912.1199%南岳生物0.007.80/0.000.00/0.000.00/泰邦生物51.6385.1065%0.003.41/13.543.41-75%中国新兴0.990.00/0.000.00/0.000.00/合计103.83157.0551%8.9015.5274%19.6315.52-21%9.纤维蛋白原：同比增长达41%，上海莱士、泰邦生物份额达59%2008-2020M12纤维蛋白原批签发数量纤维蛋白原2008-2020年CAGR为+48.53%，自2016年以来批签发量略有下滑。2020年1-12月，纤维蛋白原批签发总量为125万瓶，同比增长41%；2020Q4，纤维蛋白原批签发量为44万瓶，同比增长128%；同比增长41%；2020年12月，纤维蛋白原批签发量为7万瓶，同比增长19%。（规格换算/0.5g）2020年1-12月，纤维蛋白原共有6家公司获批签发，上海莱士获批47万瓶(份额38%)，同比增长320%；博雅生物获批24万瓶(份额19%)，同比下降13%；泰邦生物获批22万瓶(份额18%)，同比下降30%；派斯菲科获批24万瓶(份额19%)，同比增长531%；绿十字获批6万瓶(份额4%)，同比下降34%。2020M1-M12纤维蛋白原批签发情况占比数据来源：药智网，中检院，西南证券整理349.纤维蛋白原：同比增长达41%，上海莱士、泰邦生物份额达59%纤维蛋白原过去三年分季度批签发份额占比2008-2020M12纤维蛋白原批签发份额占比过去十年，纤维蛋白原批签发量最高的是上海莱士，博雅生物。近几年泰邦生物、华兰生物等公司进入纤维蛋白原市场，市场占比逐渐分散。2010-2020年11月，批签发量较高的企业分别为博雅生物(占总量8%~57%)、上海莱士(占总量13%~55%)。2020年12月派斯菲科获批24万瓶，同比增长531%；博雅生物获批24万瓶，同比下降13%。数据来源：药智网，中检院，西南证券整理359.纤维蛋白原：同比增长达41%，上海莱士、泰邦生物份额达59%2020M1-M12纤维蛋白原批签发数量及同比增速数据来源：药智网，中检院，西南证券整理36血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)环比增长2019年1-11月2020年1-11月2019年11月2020年11月2020年10月2020年11月纤维蛋白原（规格换算/0.5g）博雅生物27.3323.74-13%0.000.85/7.370.85-88%华兰生物0.240.00/0.000.00/0.000.00/派斯菲科3.8524.27531%0.001.75/17.701.75-90%上海莱士11.2947.44320%1.563.27109%0.003.27/泰邦生物31.6922.13-30%3.160.00/0.000.00/卫光生物3.202.12-34%0.001.06/0.001.06/中国新兴2.840.00/0.000.00/0.000.00/绿十字(中国）8.765.78-34%1.110.00/0.000.00/总计89.19125.4841%5.846.9319%25.076.9319%2020年1-12月血制品公司批签发情况37华兰生物:1-12月共9个品种获批。人白获批255万瓶(+4%)，静丙获批131.14万瓶(-9%)，破免获批152万瓶(+5%)，凝血因子VIII获批56万瓶(-13%)，PCC获批64万瓶(+25%)。双林生物:1-12月共4个品种获批。人白获批115万瓶(+17%)，静丙获批67万瓶(+40%)，狂免获批134万瓶(+11%)。卫光生物:1-12月共7个品种获批。人白获批119万瓶(+22%)，静丙获批72.55万瓶(+28%)，狂免获批182万瓶(+76%)，破免获批11万瓶(-56%)，免疫球蛋白获批27万瓶(-45%)。天坛生物:1-12月共8个品种获批。人白获批434万瓶(+0%)，静丙获批301万瓶(+2%)，狂免获批67万瓶(-40%)，破免获批96万瓶(-31%)，乙免获批33万瓶(-40%)。上海莱士:1-12月共9个品种获批。人白获批305万瓶(+15%)，静丙获批197万瓶(+43%)，冻干静丙获批46万瓶(+78%)，凝血因子VIII获批60万瓶(+68%)，纤原获批47万瓶(+320%)。博雅生物:1-12月共7个品种获批，人白获批135万瓶(+47%)，静丙获批64万瓶(+12%)，狂免获批82万瓶(+25%)，纤原获批24万瓶(-13%)。博晖创新:1-12月共5个品种获批。人白获批54万瓶(+26%)，狂免获批21万瓶(-18%)，免疫球蛋白获批77万瓶(+289%)，冻干静丙获批53万瓶(+6%)。泰邦生物:1-12月共9个品种获批。人白获批309万瓶(-22%)，静丙获批171.19万瓶(-15%)，PCC获批85万瓶(+65%)。共9个品种获批。2020年1-12月，破免获批152万瓶(+5%)同比平稳增长；PCC获批64万瓶(+25%)，人白获批255万瓶(+4%)，同比增速稳定；凝血因子VIII获批56万瓶(-13%)，同比下降明显。2020年12月共5种血制品获批，其中人白获批21万瓶(-35%)，破免获批7万瓶（-80%），静丙获批14万瓶(-12%)，PCC获批12万瓶(36%)，凝血因子VIII获批9万瓶(-1217%)。华兰生物(002007)：人白同比增长4%数据来源：药智网，中检院，西南证券整理2020M1-M12华兰生物批签发数量及同比增长38血制品名称企业名称规格换算后批签发数量(万支)同比增长规格换算后批签发数量(万支)同比增长2019年1-12月2020年1-12月2019年12月2020年12月人血白蛋白（规格换算/10g）华兰生物244.95255.294%32.1720.91-35%静注人免疫球蛋白（规格换算/2.5g）144.75131.14-9%12.4013.8612%狂犬病免疫球蛋白（规格换算/200IU）125.86130.564%8.3542.02404%破伤风免疫球蛋白（规格换算/250IU）145.47152.185%34.417.05-80%免疫球蛋白（规格换算/150mg）33.0236.6311%5.8312.34112%乙型肝炎免疫球蛋白（规格换算/100IU）25.5942.1165%0.000.00/凝血因子VIII（规格换算/200IU）64.9256.28-13%0.678.851217%凝血酶原复合物（规格换算/200IU）51.2164.1525%8.9012.1136%华兰生物凝血酶原复合物批签发情况(万瓶换算200IU，按年份)华兰生物凝血因子VIII批签发情况(万瓶换算200IU，按年份)数据来源：药智网，中检院，西南证券整理华兰生物人血白蛋白批签发情况(万瓶换算10g，按年份)华兰生物静丙批签发情况(万瓶换算2.5g，按年份)39华兰生物(002007)：人白同比增长4%华兰生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)华兰生物乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)数据来源：药智网，中检院，西南证券整理华兰生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)华兰生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)40华兰生物(002007)：人白同比增长4%双林生物：共4个品种获批。静丙获批67万瓶(+40%)，狂免获批134万瓶(11%)，人白获批115万瓶(+17%)。2020年12月共有3种血制品获批，人白获批17万支（+66%）；破免获批14万瓶（+107%）；静丙获批11万瓶（97%）。双林生物(000403)：静丙同比增长40%数据来源：药智网，中检院，西南证券整理2020M1-M12双林生物批签发数量及同比增长41血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-12月2020年1-12月2019年12月2020年12月人血白蛋白（规格换算/10g）双林生物98.87115.4417%10.2317.0166%静注人免疫球蛋白（规格换算/2.5g）47.8267.0340%5.5010.8397%狂犬病免疫球蛋白（规格换算/200IU）120.97134.1211%0.0032.60/破伤风免疫球蛋白（规格换算/250IU）42.3272.5271%6.6213.71107%双林生物人血白蛋白批签发情况(万瓶换算10g，按年份)双林生物静丙批签发情况(万瓶换算成2.5g，按年份)双林生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)双林生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)数据来源：药智网，中检院，西南证券整理42双林生物(000403)：静丙同比增长40%卫光生物：共7个品种获批。狂免获批203万瓶(+96%)，同比快速增长；人白获批119万瓶（+22%），同比大幅上升；免疫球蛋白获批27万瓶(-45%)，破免获批11万瓶(-56%)，同比大幅下降。2020年11月有2种血制品获批，人白获批14万瓶（+56%）；静丙获批7万瓶（-9%）。卫光生物(002880)：狂免同比增长96%，破免同比下降56%数据来源：药智网，中检院，西南证券整理2020M1-M12卫光生物批签发数量及同比增长43血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-12月2020年1-12月2019年12月2020年12月人血白蛋白（规格换算/10g）卫光生物97.48119.2722%12.0514.1617%静注人免疫球蛋白（规格换算/2.5g）56.5372.5528%7.969.1615%狂犬病免疫球蛋白（规格换算/200IU）103.83203.4396%0.0020.57/破伤风免疫球蛋白（规格换算/250IU）25.9411.38-56%4.800.00/卫光生物人血白蛋白批签发情况(万瓶换算成10g，按年份)卫光生物狂犬病免疫球蛋白批签发情况(万瓶换算成200IU，按年份)卫光生物静丙批签发情况(万瓶换算成2.5g，按年份)卫光生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)数据来源：药智网，中检院，西南证券整理卫光生物(002880)：狂免同比增长96%，破免同比下降56%44天坛生物：共8个品种获批。静丙获批301万瓶(+2%)，人白获批434万瓶(+0%)，同比小幅上升；破免获批96万瓶(-31%)，乙免获批33万瓶(-40%)，狂免获批67万瓶(-40%)，同比下降明显。2020年12月共2种血制品获批，人白获批16万瓶(-26%)，静丙获批12万瓶(11%)。天坛生物(600161)：狂免同比下降40%，破免同比下降31%数据来源：药智网，中检院，西南证券整理2020M1-M12天坛生物批签发数量及同比增长45血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-11月2020年1-11月2019年11月2020年11月人血白蛋白（规格换算/10g）天坛生物431.97433.620%21.8116.10-26%静注人免疫球蛋白（规格换算/2.5g）293.77300.652%10.8212.0211%狂犬病免疫球蛋白（规格换算/200IU）111.8966.74-40%33.410.00/破伤风免疫球蛋白（规格换算/250IU）138.8796.21-31%13.290.00/免疫球蛋白（规格换算/150mg）86.5360.12-31%76.290.00/乙型肝炎免疫球蛋白（规格换算/100IU）54.7032.91-40%15.020.00/凝血因子VIII（规格换算/200IU）0.000.37/0.000.00/免疫球蛋白（规格换算/150mg）86.5360.12-31%76.290.00/天坛生物人血白蛋白批签发情况(万瓶换算成10g，按年份)天坛生物静丙批签发情况(万瓶换算成2.5g，按年份)数据来源：药智网，中检院，西南证券整理46天坛生物(600161)：狂免同比下降40%，破免同比下降31%天坛生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)天坛生物破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)天坛生物乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)数据来源：药智网，中检院，西南证券整理天坛生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)47天坛生物(600161)：狂免同比下降40%，破免同比下降31%上海莱士：1-11月共9个品种获批，多数品种批签发量同比快速增长。纤原获批47万瓶(+320%)，人白获批305万瓶(+15%)，静丙获批197万瓶(+43%)，凝血因子VIII获批66万瓶(+67%)，冻干静丙获批46万瓶(+78%)。2020年12月共6种血制品获批，其中人白获批24万瓶（+8%），静丙获批12万瓶（-30%），冻干静注人免疫球蛋白2.3万瓶，同期无批签发，凝血因子Ⅷ获批5万瓶(55%)。上海莱士(002252)：纤原同比增长高达109%数据来源：药智网，中检院，西南证券整理2020M1-M12上海莱士批签发数量及同比增长48血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-12月2020年1-12月2019年12月2020年12月人血白蛋白（规格换算/10g）上海莱士264.53305.4015%22.5024.338%静注人免疫球蛋白（规格换算/2.5g）137.82196.9743%17.0211.98-30%狂犬病免疫球蛋白（规格换算/200IU）225.53135.51-40%15.630.00/破伤风免疫球蛋白（规格换算/250IU）39.6246.3917%0.000.00/免疫球蛋白（规格换算/150mg）28.6627.04-6%0.000.00/乙型肝炎免疫球蛋白（规格换算/100IU）50.3935.22-30%10.5320.2893%冻干静注人免疫球蛋白（规格换算/1.0g）25.9146.0278%0.002.30/凝血因子VIII（规格换算/200IU）39.2365.5367%3.295.0855%纤维蛋白原（规格换算/0.5g）11.2947.44320%1.563.27109%上海莱士人血白蛋白批签发情况(万瓶换算成10g，按年份)上海莱士静丙批签发情况(万瓶换算成2.5g，按年份)数据来源：药智网，中检院，西南证券整理49上海莱士(002252)：纤原同比增长高达109%上海莱士纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)上海莱士凝血因子VIII批签发情况(万瓶换算200IU，按年份)上海莱士破伤风免疫球蛋白批签发情况(万瓶换算250IU，按年份)上海莱士乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)上海莱士狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)上海莱士免疫球蛋白批签发情况(万瓶换算150mg，按年份)数据来源：药智网，中检院，西南证券整理50上海莱士(002252)：纤原同比增长高达109%博雅生物：1-12月共7个品种获批，人白获批135万瓶(+47%)，同比大幅增长；狂免获批82万瓶(+25%)，静丙获批63万瓶(+12%)，同比小幅上升；纤原获批24万瓶(-13%)，同比明显下降。2020年12月共3种血制品获批，人白获批3万瓶（-88%）；静丙获批5万瓶(+5%)；纤原获批0.85万瓶，同期无批签发。博雅生物(300294)：人白同比增长47%数据来源：药智网，中检院，西南证券整理2020M1-M12博雅生物批签发数量及同比增长51血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-12月2020年1-12月2019年12月2020年12月人血白蛋白（规格换算/10g）博雅生物91.64134.7647%27.103.20-88%静注人免疫球蛋白（规格换算/2.5g）56.7763.5012%5.105.345%狂犬病免疫球蛋白（规格换算/200IU）65.5782.0425%13.240.00/免疫球蛋白（规格换算/150mg）16.7550.52202%0.000.00/乙型肝炎免疫球蛋白（规格换算/100IU）0.007.35/0.000.00/纤维蛋白原（规格换算/0.5g）27.3323.74-13%0.000.85/博雅生物纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)博雅生物乙型肝炎免疫蛋白批签发情况(万瓶换算100IU，按年份)数据来源：药智网，中检院，西南证券整理博雅生物人血白蛋白批签发情况(万瓶，换算成10g，按年份)博雅生物静丙批签发情况(万瓶换算成2.5g，按年份)52博雅生物(300294)：人白同比增长47%博雅生物狂犬病免疫球蛋白批签发情况(万瓶，换算成200IU，按年份)数据来源：药智网，中检院，西南证券整理博雅生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)53博雅生物(300294)：人白同比增长47%博晖创新：1-12月共5个品种获批。整体批签发量快速增长。免疫球蛋白批签发量为77万瓶(+289%)，冻干静丙获批53万瓶(+66%)，人白获批2万瓶（-62%），同比大幅下降；狂免获批21万瓶(-18%)，同比小幅下降。22020年12月，共3种血制品获批,免疫球蛋白获批7万瓶，同期无批签发；冻干静注人免疫球蛋白获批3万瓶（-74%）。博晖创新(300318)：狂免同比减少18%数据来源：药智网，中检院，西南证券整理2020M1-M12博晖创新批签发数量及同比增长54血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-12月2020年1-12月2019年12月2020年12月破伤风免疫球蛋白（规格换算/250IU）博晖创新5.251.98-62%0.000.00/免疫球蛋白（规格换算/150mg）19.8977.29289%0.006.80/狂犬病免疫球蛋白（规格换算/200IU）26.1521.37-18%0.000.00/冻干静注人免疫球蛋白（规格换算/1.0g）32.1853.3066%9.722.57-74%人血白蛋白（规格换算/10g）42.7353.8426%6.842.85-58%数据来源：药智网，中检院，西南证券整理55博晖创新(300318)：狂免同比减少18%博晖创新人血白蛋白批签发情况(万瓶换算成10g，按年份)博晖创新冻干静丙批签发情况(万瓶换算成2.5g，按年份)博晖创新狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)博晖创新破伤风免疫球蛋白批签发情况(万瓶换算150mg，按年份)博晖创新免疫球蛋白批签发情况(万瓶换算成150mg，按年份)数据来源：药智网，中检院，西南证券整理56博晖创新(300318)：狂免同比减少18%泰邦生物：1-12月共9个品种获批。PCC获批85万瓶(+65%)，同比快速增长；人白获批309万瓶(-22%)，同比明显下降。2020年12月共4种血制品获批，PCC获批3万瓶，同期无批签发；静丙获批6万瓶(83%)，狂免获批14万瓶（-40%）。泰邦生物(CBPO.O)：PCC同比增长超50%数据来源：药智网，中检院，西南证券整理2020M1-M12泰邦生物批签发数量及同比增长57血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-12月2020年1-12月2019年12月2020年12月人血白蛋白（规格换算/10g）泰邦生物395.06308.67-22%36.178.44-77%静注人免疫球蛋白（规格换算/2.5g）200.55171.19-15%3.476.3383%狂犬病免疫球蛋白（规格换算/200IU）186.66162.19-13%23.9914.35-40%破伤风免疫球蛋白（规格换算/250IU）149.74136.38-9%15.660.00/免疫球蛋白批签发量（万瓶）18.119.28-49%9.500.00/乙型肝炎免疫球蛋白（规格换算/100IU）25.0226.295%0.000.00/凝血因子VIII（规格换算/200IU）54.4047.79-12%3.820.00/凝血酶原复合物（规格换算/200IU）51.6385.1065%0.003.41/纤维蛋白原（规格换算/0.5g）31.6922.13-30%3.160.00/泰邦生物凝血因子VIII批签发情况(万瓶换算200IU，按年份)泰邦生物狂犬病免疫球蛋白批签发情况(万瓶换算200IU，按年份)泰邦生物静丙批签发情况(万瓶换算成2.5g，按年份)泰邦生物人血白蛋白批签发情况(万瓶换算成10g，按年份)数据来源：药智网，中检院，西南证券整理58泰邦生物(CBPO.O)：PCC同比增长超50%泰邦生物破伤风免疫球蛋白批签发情况(万瓶换算150mg，按年份)泰邦生物乙肝免疫球蛋白批签发情况(万瓶换算100IU，按年份)泰邦生物凝血酶原复合物批签发情况(万瓶换算200IU，按年份)数据来源：药智网，中检院，西南证券整理59泰邦生物(CBPO.O)：PCC同比增长超50%泰邦生物纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)泰邦生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)数据来源：药智网，中检院，西南证券整理60泰邦生物(CBPO.O)：PCC同比增长超50%西南证券研究发展中心西南证券投资评级说明公司评级买入：未来6个月内，个股相对沪深300指数涨幅在20%以上持有：未来6个月内，个股相对沪深300指数涨幅介于10%与20%之间中性：未来6个月内，个股相对沪深300指数涨幅介于-10%与10%之间回避：未来6个月内，个股相对沪深300指数涨幅介于-20%与-10%之间卖出：未来6个月内，个股相对沪深300指数涨幅在-20%以下行业评级强于大市：未来6个月内，行业整体回报高于沪深300指数5%以上跟随大市：未来6个月内，行业整体回报介于沪深300指数-5%与5%之间弱于大市：未来6个月内，行业整体回报低于沪深300指数-5%以下分析师承诺报告署名分析师具有中国证券业协会授予的证券投资咨询执业资格并注册为证券分析师，报告所采用的数据均来自合法合规渠道，分析逻辑基于分析师的职业理解，通过合理判断得出结论，独立、客观地出具本报告。分析师承诺不曾因，不因，也将不会因本报告中的具体推荐意见或观点而直接或间接获取任何形式的补偿。重要声明西南证券股份有限公司（以下简称“本公司”）具有中国证券监督管理委员会核准的证券投资咨询业务资格。本公司与作者在自身所知情范围内，与本报告中所评价或推荐的证券不存在法律法规要求披露或采取限制、静默措施的利益冲突。《证券期货投资者适当性管理办法》于2017年7月1日起正式实施，本报告仅供本公司客户中的专业投资者使用，若您并非本公司客户中的专业投资者，为控制投资风险，请取消接收、订阅或使用本报告中的任何信息。本公司也不会因接收人收到、阅读或关注自媒体推送本报告中的内容而视其为客户。本公司或关联机构可能会持有报告中提到的公司所发行的证券并进行交易，还可能为这些公司提供或争取提供投资银行或财务顾问服务。本报告中的信息均来源于公开资料，本公司对这些信息的准确性、完整性或可靠性不作任何保证。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断，本报告所指的证券或投资标的的价格、价值及投资收入可升可跌，过往表现不应作为日后的表现依据。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告，本公司不保证本报告所含信息保持在最新状态。同时，本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。本报告仅供参考之用，不构成出售或购买证券或其他投资标的要约或邀请。在任何情况下，本报告中的信息和意见均不构成对任何个人的投资建议。投资者应结合自己的投资目标和财务状况自行判断是否采用本报告所载内容和信息并自行承担风险，本公司及雇员对投资者使用本报告及其内容而造成的一切后果不承担任何法律责任。本报告及附录版权为西南证券所有，未经书面许可，任何机构和个人不得以任何形式翻版、复制和发布。如引用须注明出处为“西南证券”，且不得对本报告及附录进行有悖原意的引用、删节和修改。未经授权刊载或者转发本报告及附录的，本公司将保留向其追究法律责任的权利。西南证券研究发展中心上海重庆地址：上海市浦东新区陆家嘴东路166号中国保险大厦20楼地址：重庆市江北区桥北苑8号西南证券大厦3楼邮编：200120邮编：400023北京深圳地址：北京市西城区南礼士路66号建威大厦1501-1502地址：深圳市福田区深南大道6023号创建大厦4楼邮编：100045邮编：518040西南证券机构销售团队区域姓名职务座机手机邮箱上海蒋诗烽地区销售总监021-6841530918621310081jsf@swsc.com.cn张方毅高级销售经理021-6841395915821376156zfyi@swsc.com.cn吴菲阳销售经理021-6841502016621045018wfy@swsc.com.cn付禹销售经理021-6841552313761585788fuyu@swsc.com.cn黄滢销售经理1881821559318818215593hying@swsc.com.cn蒋俊洲销售经理1851651610518516516105jiangjz@swsc.com.cn刘琦销售经理1861275119218612751192liuqi@swsc.com.cn崔露文销售经理1564296031515642960315clw@swsc.com.cn陈慧琳销售经理1852348777518523487775chhl@swsc.com.cn北京张岚高级销售经理1860124180318601241803zhanglan@swsc.com.cn彭博销售经理1339169933913391699339pbyf@swsc.com.cn广深王湘杰地区销售副总监0755-2667151713480920685wxj@swsc.com.cn林芷豌高级销售经理1501258512215012585122linzw@swsc.com.cn陈慧玲高级销售经理1850070933018500709330chl@swsc.com.cn谭凌岚销售经理1364236260113642362601tll@swsc.com.cn郑龑销售经理1882518974418825189744zhengyan@swsc.com.cn西南证券研究发展中心前沿报告库是中国新经济产业咨询报告共享平台。行业范围涵盖新一代信息技术、5G、物联网、新能源、新材料、新消费、大健康、大数据、智能制造等新兴领域。为企事业单位、科研院所、投融资机构等提供研究和决策参考。扫一扫免费获取海量报告","data":[{"id":"1","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，人血白蛋白批签发总量为5989万瓶(+13%)，","content_offset":["142","177"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5989万瓶","164","170"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","153","158"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，人血白蛋白批签发总量为5989万瓶(+13%)，","content_offset":["142","177"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+13%","171","175"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","153","158"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发总量为2107万瓶(-1%)","content_offset":["177","203"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2107万瓶","192","198"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","181","186"],"渠道":["国产","179","181"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发总量为2107万瓶(-1%)","content_offset":["177","203"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-1%","199","202"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","181","186"],"渠道":["国产","179","181"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比为35%","content_offset":["204","210"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["35%","207","210"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","126","131"],"渠道":["国产","179","181"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发总量为3882万瓶(+23%)","content_offset":["211","236"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3882万瓶","224","230"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","213","218"],"渠道":["进口","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发总量为3882万瓶(+23%)","content_offset":["211","236"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+23%","231","235"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","213","218"],"渠道":["进口","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比为65%","content_offset":["237","243"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["65%","240","243"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","153","158"],"渠道":["进口","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，静丙（规格换算/2.5g）批签发总量为1238万瓶","content_offset":["250","286"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1238万瓶","280","286"],"indicator_element":{"时间":["2020年1-12月","250","260"],"产品":["静丙","261","263"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长5%","content_offset":["287","293"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["5%","291","293"],"indicator_element":{"时间":["2020年1-12月","250","260"],"产品":["静丙","261","263"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中，2020年12月静丙批签发量为79万瓶","content_offset":["294","316"],"indicators":[{"indicator_name":"批签发量","indicator_value":["79万瓶","312","316"],"indicator_element":{"时间":["2020年12月","297","305"],"产品":["静丙","305","307"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降8%","content_offset":["317","323"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降8%","319","323"],"indicator_element":{"时间":["2020年12月","297","305"],"产品":["静丙","261","263"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其他品种如狂免（规格换算/200IU）1186万瓶(-3%)、破免（规格换算/250IU）602万瓶(-5%)、免疫球蛋白（规格换算/150mg）470万瓶(+79%)","content_offset":["324","408"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1186万瓶","343","349"],"indicator_element":{"产品":["免疫球蛋白","380","385"],"时间":["2020年12月","297","305"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["602万瓶","369","374"],"indicator_element":{"产品":["免疫球蛋白","380","385"],"时间":["2020年12月","297","305"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["470万瓶","397","402"],"indicator_element":{"产品":["免疫球蛋白","380","385"],"时间":["2020年12月","297","305"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其他品种如狂免（规格换算/200IU）1186万瓶(-3%)、破免（规格换算/250IU）602万瓶(-5%)、免疫球蛋白（规格换算/150mg）470万瓶(+79%)","content_offset":["324","408"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-3%","350","353"],"indicator_element":{"产品":["免疫球蛋白","380","385"],"时间":["2020年12月","297","305"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["-5%","375","378"],"indicator_element":{"产品":["免疫球蛋白","380","385"],"时间":["2020年12月","297","305"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+79%","403","407"],"indicator_element":{"产品":["免疫球蛋白","380","385"],"时间":["2020年12月","297","305"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"凝血因子VIII（规格换算/200IU）199万瓶(+7%)、PCC（规格换算/200IU）157万瓶(+51%)、纤原（规格换算/0.5g）125万瓶(+41%)","content_offset":["415","497"],"indicators":[{"indicator_name":"批签发量","indicator_value":["199万瓶","435","440"],"indicator_element":{"产品":["纤原","473","475"],"时间":["2020年12月","1202","1210"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["157万瓶","461","466"],"indicator_element":{"产品":["纤原","473","475"],"时间":["2020年12月","1202","1210"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["125万瓶","486","491"],"indicator_element":{"产品":["纤原","473","475"],"时间":["2020年12月","1202","1210"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"凝血因子VIII（规格换算/200IU）199万瓶(+7%)、PCC（规格换算/200IU）157万瓶(+51%)、纤原（规格换算/0.5g）125万瓶(+41%)","content_offset":["415","497"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7%","442","444"],"indicator_element":{"产品":["纤原","473","475"],"时间":["2020年12月","1202","1210"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["51%","468","471"],"indicator_element":{"产品":["纤原","473","475"],"时间":["2020年12月","1202","1210"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["41%","493","496"],"indicator_element":{"产品":["纤原","473","475"],"时间":["2020年12月","1202","1210"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"人血白蛋白：1-12月同比增长13%","content_offset":["2074","2092"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["13%","2089","2092"],"indicator_element":{"时间":["1-12月","2080","2085"],"产品":["人血白蛋白","2074","2079"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比+0.3%","content_offset":["2102","2115"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+0.3%","2110","2115"],"indicator_element":{"时间":["2020Q4","2102","2108"],"产品":["人血白蛋白","2074","2079"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比-7%","content_offset":["2116","2124"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-7%","2121","2124"],"indicator_element":{"时间":["12月","2116","2119"],"产品":["人血白蛋白","2074","2079"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"静丙：1-12月同比增长5%","content_offset":["2127","2141"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["5%","2139","2141"],"indicator_element":{"时间":["1-12月","2130","2135"],"产品":["静丙","2127","2129"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比-15%","content_offset":["2156","2168"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-15%","2164","2168"],"indicator_element":{"时间":["2020Q4","2156","2162"],"产品":["静丙","2127","2129"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比-8%","content_offset":["2169","2177"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-8%","2174","2177"],"indicator_element":{"时间":["12月","2169","2172"],"产品":["静丙","2127","2129"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"狂犬病免疫球蛋白：1-12月同比下降3%","content_offset":["2180","2200"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降3%","2196","2200"],"indicator_element":{"时间":["1-12月","2189","2194"],"产品":["狂犬病免疫球蛋白","2180","2188"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比-15%","content_offset":["2156","2168"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-15%","2164","2168"],"indicator_element":{"时间":["2020Q4","2156","2162"],"产品":["狂犬病免疫球蛋白","2180","2188"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比+4%","content_offset":["2225","2233"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+4%","2230","2233"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["狂犬病免疫球蛋白","2180","2188"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"破伤风免疫球蛋白：1-12月同比下降5%","content_offset":["2236","2256"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","2252","2256"],"indicator_element":{"时间":["1-12月","2245","2250"],"产品":["破伤风免疫球蛋白","2236","2244"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比下降5%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","7","11"],"indicator_element":{"时间":["2020Q4","-1","5"],"产品":["破伤风免疫球蛋白","1579","1587"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比下降5%","content_offset":["2247","2256"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","2252","2256"],"indicator_element":{"时间":["12月","2247","2250"],"产品":["破伤风免疫球蛋白","2236","2244"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"免疫球蛋白：1-12月同比增长下降5%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","14","18"],"indicator_element":{"时间":["1-12月","5","10"],"产品":["免疫球蛋白","-1","4"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比下降5%","content_offset":["-1","-1"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","7","11"],"indicator_element":{"时间":["2020Q4","-1","5"],"产品":["免疫球蛋白","244","249"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比下降5%","content_offset":["2247","2256"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","2252","2256"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["免疫球蛋白","2183","2188"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"乙肝免疫球蛋白：1-12月同比增长6%","content_offset":["2353","2372"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["6%","2370","2372"],"indicator_element":{"时间":["1-12月","2361","2366"],"产品":["乙肝免疫球蛋白","2353","2360"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比+4%","content_offset":["2382","2393"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+4%","2390","2393"],"indicator_element":{"时间":["2020Q4","2382","2388"],"产品":["乙肝免疫球蛋白","2353","2360"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比29%","content_offset":["2394","2402"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["29%","2399","2402"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["乙肝免疫球蛋白","2353","2360"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"凝血因子Ⅷ：1-12月同比增长达7%","content_offset":["2405","2423"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7%","2421","2423"],"indicator_element":{"时间":["1-12月","2411","2416"],"产品":["凝血因子Ⅷ","2405","2410"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比-40%","content_offset":["2440","2452"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["40%","2449","2452"],"indicator_element":{"时间":["2020Q4","2440","2446"],"产品":["凝血因子Ⅷ","2405","2410"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比39%","content_offset":["2453","2461"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["39%","2458","2461"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["凝血因子Ⅷ","2405","2410"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"凝血酶原复合物：1-12月同比增长51%","content_offset":["2464","2484"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["51%","2481","2484"],"indicator_element":{"时间":["1-12月","2472","2477"],"产品":["凝血酶原复合物","2464","2471"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比+171%","content_offset":["2499","2512"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+171%","2507","2512"],"indicator_element":{"时间":["2020Q4","2499","2505"],"产品":["凝血酶原复合物","2464","2471"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比+74%","content_offset":["2513","2522"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+74%","2518","2522"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["凝血酶原复合物","2464","2471"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"纤维蛋白原：1-12月同比增长达41%","content_offset":["2525","2544"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["41%","2541","2544"],"indicator_element":{"时间":["1-12月","2531","2536"],"产品":["纤维蛋白原","2525","2530"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4同比+128%","content_offset":["2561","2574"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+128%","2569","2574"],"indicator_element":{"时间":["2020Q4","2561","2567"],"产品":["纤维蛋白原","2525","2530"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"12月同比+19%","content_offset":["2575","2584"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+19%","2580","2584"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["纤维蛋白原","2525","2530"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2007-2020年人血白蛋白批签发复合年均增长率(CAGR)为+21.61%","content_offset":["3403","3442"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+21.61%","3435","3442"],"indicator_element":{"时间":["2007-2020年","3403","3413"],"产品":["人血白蛋白","3413","3418"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2019年，国内人血白蛋白批签发量为5285万瓶(+11%)","content_offset":["3443","3473"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5285万瓶","3461","3467"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","3451","3456"],"区域":["国内","3449","3451"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2019年，国内人血白蛋白批签发量为5285万瓶(+11%)","content_offset":["3443","3473"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11%","3468","3472"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","3451","3456"],"区域":["国内","3449","3451"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产批签发为2120万瓶(+13%)","content_offset":["3474","3494"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2120万瓶","3482","3488"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","3413","3418"],"渠道":["国产","3476","3478"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产批签发为2120万瓶(+13%)","content_offset":["3474","3494"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+13%","3489","3493"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","3413","3418"],"渠道":["国产","3476","3478"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比40%","content_offset":["1371","1376"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["40%","1373","1376"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","2074","2079"],"渠道":["国产","1318","1320"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口批签发为3165万瓶(+11%)","content_offset":["3501","3519"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3165万瓶","3507","3513"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","3413","3418"],"渠道":["进口","3501","3503"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口批签发为3165万瓶(+11%)","content_offset":["3501","3519"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11%","3514","3518"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","3413","3418"],"渠道":["进口","3501","3503"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比60%","content_offset":["1295","1300"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["60%","1297","1300"],"indicator_element":{"时间":["2019年","3443","3448"],"产品":["人血白蛋白","1226","1231"],"渠道":["进口","1241","1243"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，人血白蛋白批签发总量为5989万瓶(+13%)，","content_offset":["142","177"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5989万瓶","164","170"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","153","158"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，人血白蛋白批签发总量为5989万瓶(+13%)，","content_offset":["142","177"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+13%","171","175"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","153","158"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发总量为2107万瓶(-1%)","content_offset":["177","203"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2107万瓶","192","198"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","181","186"],"渠道":["国产","179","181"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发总量为2107万瓶(-1%)","content_offset":["177","203"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-1%","199","202"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","181","186"],"渠道":["国产","179","181"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比为35%","content_offset":["204","210"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["35%","207","210"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","126","131"],"渠道":["国产","179","181"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发总量为3882万瓶(+23%)","content_offset":["211","236"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3882万瓶","224","230"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","213","218"],"渠道":["进口","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发总量为3882万瓶(+23%)","content_offset":["211","236"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+23%","231","235"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","213","218"],"渠道":["进口","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比为65%","content_offset":["237","243"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["65%","240","243"],"indicator_element":{"时间":["2020年1-12月","142","152"],"产品":["人血白蛋白","153","158"],"渠道":["进口","211","213"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4人血白蛋白批签发总量为1435万瓶(+0.3%)","content_offset":["3639","3669"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1435万瓶","3656","3662"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3645","3650"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4人血白蛋白批签发总量为1435万瓶(+0.3%)","content_offset":["3639","3669"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+0.3%","3663","3668"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3645","3650"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发量为439万瓶(-12%)","content_offset":["3670","3695"],"indicators":[{"indicator_name":"批签发量","indicator_value":["439万瓶","3684","3689"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3674","3679"],"渠道":["国产","3672","3674"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发量为439万瓶(-12%)","content_offset":["3670","3695"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-12%","3690","3694"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3674","3679"],"渠道":["国产","3672","3674"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比31%","content_offset":["3696","3701"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["31%","3698","3701"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3608","3613"],"渠道":["国产","3672","3674"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发量为996万瓶(+7%)","content_offset":["3702","3724"],"indicators":[{"indicator_name":"批签发量","indicator_value":["996万瓶","3714","3719"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3704","3709"],"渠道":["进口","3702","3704"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发量为996万瓶(+7%)","content_offset":["3702","3724"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+7%","3720","3723"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3704","3709"],"渠道":["进口","3702","3704"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比69%","content_offset":["3725","3730"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["69%","3727","3730"],"indicator_element":{"时间":["2020Q4","3639","3645"],"产品":["人血白蛋白","3645","3650"],"渠道":["进口","3702","3704"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月人血白蛋白批签发总量为521万瓶(-7%)","content_offset":["3731","3760"],"indicators":[{"indicator_name":"批签发量","indicator_value":["521万瓶","3750","3755"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3739","3744"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月人血白蛋白批签发总量为521万瓶(-7%)","content_offset":["3731","3760"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-7%","3756","3759"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3739","3744"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发量为151万瓶(-27%)","content_offset":["3761","3786"],"indicators":[{"indicator_name":"批签发量","indicator_value":["151万瓶","3775","3780"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3765","3770"],"渠道":["国产","3763","3765"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中国产人血白蛋白批签发量为151万瓶(-27%)","content_offset":["3761","3786"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["-27%","3781","3785"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3765","3770"],"渠道":["国产","3763","3765"]},"indicator_supplement":{"属性":""}}]},{"id":"73","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比29%","content_offset":["3787","3792"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["29%","3789","3792"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3704","3709"],"渠道":["国产","3763","3765"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发量为370万瓶(+5%)","content_offset":["3793","3815"],"indicators":[{"indicator_name":"批签发量","indicator_value":["370万瓶","3805","3810"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3795","3800"],"渠道":["进口","3793","3795"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发量为370万瓶(+5%)","content_offset":["3793","3815"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+5%","3811","3814"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3795","3800"],"渠道":["进口","3793","3795"]},"indicator_supplement":{"属性":""}}]},{"id":"76","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"占比71%","content_offset":["3816","3821"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["71%","3818","3821"],"indicator_element":{"时间":["2020年12月","3731","3739"],"产品":["人血白蛋白","3739","3744"],"渠道":["进口","3793","3795"]},"indicator_supplement":{"属性":""}}]},{"id":"77","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"进口人血白蛋白批签发量2007年-2020年CAGR(年均复合增长率)为+32.88%","content_offset":["4293","4336"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+32.88%","4329","4336"],"indicator_element":{"时间":["2007年-2020年","4304","4315"],"产品":["人血白蛋白","4295","4300"],"渠道":["进口","4293","4295"]},"indicator_supplement":{"属性":""}}]},{"id":"78","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"国产人血白蛋白批签发量2007-2020年CAGR为+16%","content_offset":["5428","5458"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+16%","5454","5458"],"indicator_element":{"时间":["2007年-2020年","5903","5914"],"产品":["人血白蛋白","5430","5435"],"渠道":["国产","5428","5430"]},"indicator_supplement":{"属性":""}}]},{"id":"79","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"静丙批签发量2007-2020年CAGR为+16%","content_offset":["7062","7087"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+16%","7083","7087"],"indicator_element":{"时间":["2007年-2020年","7418","7429"],"产品":["静丙","7062","7064"]},"indicator_supplement":{"属性":""}}]},{"id":"80","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，静丙批签发总量为1238万瓶","content_offset":["7089","7114"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1238万瓶","7108","7114"],"indicator_element":{"时间":["2020年1-12月","7089","7099"],"产品":["静丙","7100","7102"]},"indicator_supplement":{"属性":""}}]},{"id":"81","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长5%","content_offset":["287","293"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["5%","291","293"],"indicator_element":{"时间":["2020年1-12月","250","260"],"产品":["静丙","261","263"]},"indicator_supplement":{"属性":""}}]},{"id":"82","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"其中，2020Q4静丙批签发量为234.15万瓶","content_offset":["7122","7146"],"indicators":[{"indicator_name":"批签发量","indicator_value":["234.15万瓶","7138","7146"],"indicator_element":{"时间":["2020Q4","7125","7131"],"产品":["静丙","7131","7133"]},"indicator_supplement":{"属性":""}}]},{"id":"83","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降15%","content_offset":["7147","7154"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降15%","7149","7154"],"indicator_element":{"时间":["2020Q4","7125","7131"],"产品":["静丙","7062","7064"]},"indicator_supplement":{"属性":""}}]},{"id":"84","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月静丙批签发量为79万瓶","content_offset":["297","316"],"indicators":[{"indicator_name":"批签发量","indicator_value":["79万瓶","312","316"],"indicator_element":{"时间":["2020年12月","297","305"],"产品":["静丙","305","307"]},"indicator_supplement":{"属性":""}}]},{"id":"85","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降8%","content_offset":["317","323"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降8%","319","323"],"indicator_element":{"时间":["2020年12月","297","305"],"产品":["静丙","261","263"]},"indicator_supplement":{"属性":""}}]},{"id":"86","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"狂犬病免疫球蛋白批签发量2008-2020复合年均增长率(CAGR)为+19%","content_offset":["8499","8538"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+19%","8534","8538"],"indicator_element":{"时间":["2008-2020","8511","8520"],"产品":["狂犬病免疫球蛋白","8499","8507"]},"indicator_supplement":{"属性":""}}]},{"id":"87","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月狂犬病免疫球蛋白批签发总量为1186万瓶","content_offset":["8558","8588"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1186万瓶","8582","8588"],"indicator_element":{"时间":["2020年1-12月","8558","8568"],"产品":["狂犬病免疫球蛋白","8568","8576"]},"indicator_supplement":{"属性":""}}]},{"id":"88","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降3%","content_offset":["2194","2200"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降3%","2196","2200"],"indicator_element":{"时间":["2020年1-12月","2585","2595"],"产品":["狂犬病免疫球蛋白","2180","2188"]},"indicator_supplement":{"属性":""}}]},{"id":"89","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4狂犬病免疫球蛋白批签发量为330万瓶","content_offset":["8596","8620"],"indicators":[{"indicator_name":"批签发量","indicator_value":["330万瓶","8615","8620"],"indicator_element":{"时间":["2020Q4","8596","8602"],"产品":["狂犬病免疫球蛋白","8602","8610"]},"indicator_supplement":{"属性":""}}]},{"id":"90","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升8%","content_offset":["8621","8627"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["8%","8625","8627"],"indicator_element":{"时间":["2020Q4","8596","8602"],"产品":["狂犬病免疫球蛋白","8568","8576"]},"indicator_supplement":{"属性":""}}]},{"id":"91","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月狂犬病免疫球蛋白批签发量为119万瓶","content_offset":["8628","8654"],"indicators":[{"indicator_name":"批签发量","indicator_value":["119万瓶","8649","8654"],"indicator_element":{"时间":["2020年12月","8628","8636"],"产品":["狂犬病免疫球蛋白","8636","8644"]},"indicator_supplement":{"属性":""}}]},{"id":"92","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升4%","content_offset":["8655","8661"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["4%","8659","8661"],"indicator_element":{"时间":["2020年12月","8628","8636"],"产品":["狂犬病免疫球蛋白","8568","8576"]},"indicator_supplement":{"属性":""}}]},{"id":"93","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"破伤风免疫球蛋白批签发量2008-2020年复合年均增长率(CAGR)为+10.77%","content_offset":["9887","9930"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+10.77%","9923","9930"],"indicator_element":{"时间":["2008-2020年","9899","9909"],"产品":["破伤风免疫球蛋白","9887","9895"]},"indicator_supplement":{"属性":""}}]},{"id":"94","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，破伤风免疫球蛋白批签发总量为602万瓶","content_offset":["9960","9990"],"indicators":[{"indicator_name":"批签发量","indicator_value":["602万瓶","9985","9990"],"indicator_element":{"时间":["2020年1-12月","9960","9970"],"产品":["破伤风免疫球蛋白","9971","9979"]},"indicator_supplement":{"属性":""}}]},{"id":"95","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降5%","content_offset":["2250","2256"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降5%","2252","2256"],"indicator_element":{"时间":["2020年1-12月","2585","2595"],"产品":["破伤风免疫球蛋白","2236","2244"]},"indicator_supplement":{"属性":""}}]},{"id":"96","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4，破伤风免疫球蛋白批签发量为190万瓶","content_offset":["9998","10023"],"indicators":[{"indicator_name":"批签发量","indicator_value":["190万瓶","10018","10023"],"indicator_element":{"时间":["2020Q4","9998","10004"],"产品":["破伤风免疫球蛋白","10005","10013"]},"indicator_supplement":{"属性":""}}]},{"id":"97","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升37%","content_offset":["10024","10031"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["37%","10028","10031"],"indicator_element":{"时间":["2020Q4","9998","10004"],"产品":["破伤风免疫球蛋白","9935","9943"]},"indicator_supplement":{"属性":""}}]},{"id":"98","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月份，破伤风免疫球蛋白批签发量为21万瓶","content_offset":["10032","10059"],"indicators":[{"indicator_name":"批签发量","indicator_value":["21万瓶","10055","10059"],"indicator_element":{"时间":["2020年12月","10032","10040"],"产品":["破伤风免疫球蛋白","10042","10050"]},"indicator_supplement":{"属性":""}}]},{"id":"99","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降74%","content_offset":["10060","10067"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降74%","10062","10067"],"indicator_element":{"时间":["2020年12月","10032","10040"],"产品":["破伤风免疫球蛋白","9971","9979"]},"indicator_supplement":{"属性":""}}]},{"id":"100","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"免疫球蛋白批签发量2008-2020复合增长率(CAGR)为+9.86%","content_offset":["11271","11307"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+9.86%","11301","11307"],"indicator_element":{"时间":["2008-2020","11280","11289"],"产品":["免疫球蛋白","11271","11276"]},"indicator_supplement":{"属性":""}}]},{"id":"101","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，免疫球蛋白批签发量为470万瓶","content_offset":["11339","11365"],"indicators":[{"indicator_name":"批签发量","indicator_value":["470万瓶","11360","11365"],"indicator_element":{"时间":["2020年1-12月","11339","11349"],"产品":["免疫球蛋白","11350","11355"]},"indicator_supplement":{"属性":""}}]},{"id":"102","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长79%","content_offset":["2305","2312"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["79%","2309","2312"],"indicator_element":{"时间":["2020年1-12月","2585","2595"],"产品":["免疫球蛋白","2239","2244"]},"indicator_supplement":{"属性":""}}]},{"id":"103","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4，免疫球蛋白批签发量为230万瓶","content_offset":["11374","11396"],"indicators":[{"indicator_name":"批签发量","indicator_value":["230万瓶","11391","11396"],"indicator_element":{"时间":["2020Q4","11374","11380"],"产品":["免疫球蛋白","11381","11386"]},"indicator_supplement":{"属性":""}}]},{"id":"104","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升55%","content_offset":["11397","11404"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["55%","11401","11404"],"indicator_element":{"时间":["2020Q4","11374","11380"],"产品":["免疫球蛋白","11308","11313"]},"indicator_supplement":{"属性":""}}]},{"id":"105","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月，免疫球蛋白批签发量为128万瓶","content_offset":["11405","11429"],"indicators":[{"indicator_name":"批签发量","indicator_value":["128万瓶","11424","11429"],"indicator_element":{"时间":["2020年12月","11405","11413"],"产品":["免疫球蛋白","11414","11419"]},"indicator_supplement":{"属性":""}}]},{"id":"106","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升40%","content_offset":["11430","11437"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["40%","11434","11437"],"indicator_element":{"时间":["2020年12月","11405","11413"],"产品":["免疫球蛋白","11350","11355"]},"indicator_supplement":{"属性":""}}]},{"id":"107","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"乙肝免疫球蛋白2007-2020复合增长率(CAGR)为-1.07%","content_offset":["12758","12792"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["-1.07%","12786","12792"],"indicator_element":{"时间":["2007-2020","12765","12774"],"产品":["乙肝免疫球蛋白","12758","12765"]},"indicator_supplement":{"属性":""}}]},{"id":"108","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，乙肝免疫球蛋白批签发总量为218万瓶","content_offset":["12794","12823"],"indicators":[{"indicator_name":"批签发量","indicator_value":["218万瓶","12818","12823"],"indicator_element":{"时间":["2020年1-12月","12794","12804"],"产品":["乙肝免疫球蛋白","12805","12812"]},"indicator_supplement":{"属性":""}}]},{"id":"109","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升6%","content_offset":["12824","12830"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["6%","12828","12830"],"indicator_element":{"时间":["2020年1-12月","12794","12804"],"产品":["乙肝免疫球蛋白","12739","12746"]},"indicator_supplement":{"属性":""}}]},{"id":"110","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4，乙肝免疫球蛋白批签发量为83万瓶","content_offset":["12831","12854"],"indicators":[{"indicator_name":"批签发量","indicator_value":["83万瓶","12850","12854"],"indicator_element":{"时间":["2020Q4","12831","12837"],"产品":["乙肝免疫球蛋白","12838","12845"]},"indicator_supplement":{"属性":""}}]},{"id":"111","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升4%","content_offset":["8655","8661"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["4%","8659","8661"],"indicator_element":{"时间":["2020Q4","8596","8602"],"产品":["乙肝免疫球蛋白","12667","12674"]},"indicator_supplement":{"属性":""}}]},{"id":"112","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月份，乙肝免疫球蛋白批签发量为33万瓶","content_offset":["12862","12888"],"indicators":[{"indicator_name":"批签发量","indicator_value":["33万瓶","12884","12888"],"indicator_element":{"时间":["2020年12月","12862","12870"],"产品":["乙肝免疫球蛋白","12872","12879"]},"indicator_supplement":{"属性":""}}]},{"id":"113","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升29%","content_offset":["12889","12896"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["29%","12893","12896"],"indicator_element":{"时间":["2020年12月","12862","12870"],"产品":["乙肝免疫球蛋白","12805","12812"]},"indicator_supplement":{"属性":""}}]},{"id":"114","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"凝血因子VIII行业2008-2020年CAGR为-2%","content_offset":["13849","13877"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["-2%","13874","13877"],"indicator_element":{"时间":["2008-2020年","13859","13869"],"产品":["凝血因子Ⅷ","13797","13802"]},"indicator_supplement":{"属性":""}}]},{"id":"115","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，凝血因子Ⅷ批签发总量为199万瓶","content_offset":["13896","13923"],"indicators":[{"indicator_name":"批签发量","indicator_value":["199万瓶","13918","13923"],"indicator_element":{"时间":["2020年1-12月","13896","13906"],"产品":["凝血因子Ⅷ","13907","13912"]},"indicator_supplement":{"属性":""}}]},{"id":"116","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长7%","content_offset":["13924","13930"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7%","13928","13930"],"indicator_element":{"时间":["2020年1-12月","13896","13906"],"产品":["凝血因子Ⅷ","13838","13843"]},"indicator_supplement":{"属性":""}}]},{"id":"117","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4，凝血因子Ⅷ批签发量为33万瓶","content_offset":["13931","13952"],"indicators":[{"indicator_name":"批签发量","indicator_value":["33万瓶","13948","13952"],"indicator_element":{"时间":["2020Q4","13931","13937"],"产品":["凝血因子Ⅷ","13938","13943"]},"indicator_supplement":{"属性":""}}]},{"id":"118","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比下降-40%","content_offset":["13953","13961"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降-40%","13955","13961"],"indicator_element":{"时间":["2020Q4","13931","13937"],"产品":["凝血因子Ⅷ","13907","13912"]},"indicator_supplement":{"属性":""}}]},{"id":"119","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月，凝血因子Ⅷ批签发量为14万瓶","content_offset":["13962","13985"],"indicators":[{"indicator_name":"批签发量","indicator_value":["14万瓶","13981","13985"],"indicator_element":{"时间":["2020年12月","13962","13970"],"产品":["凝血因子Ⅷ","13971","13976"]},"indicator_supplement":{"属性":""}}]},{"id":"120","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升39%","content_offset":["13986","13993"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["39%","13990","13993"],"indicator_element":{"时间":["2020年12月","13962","13970"],"产品":["凝血因子Ⅷ","13907","13912"]},"indicator_supplement":{"属性":""}}]},{"id":"121","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"凝血酶原复合物批签发2008-2020年CAGR为+30.06%","content_offset":["14958","14990"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+30.06%","14983","14990"],"indicator_element":{"时间":["2008-2020年","14968","14978"],"产品":["凝血酶原复合物","14958","14965"]},"indicator_supplement":{"属性":""}}]},{"id":"122","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，凝血酶原复合物批签发总量为157万瓶","content_offset":["15059","15088"],"indicators":[{"indicator_name":"批签发量","indicator_value":["157万瓶","15083","15088"],"indicator_element":{"时间":["2020年1-12月","15059","15069"],"产品":["凝血酶原复合物","15070","15077"]},"indicator_supplement":{"属性":""}}]},{"id":"123","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长51%","content_offset":["2477","2484"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["51%","2481","2484"],"indicator_element":{"时间":["2020年1-12月","2585","2595"],"产品":["凝血酶原复合物","2464","2471"]},"indicator_supplement":{"属性":""}}]},{"id":"124","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4，凝血酶原复合物批签发量为66万瓶","content_offset":["15097","15120"],"indicators":[{"indicator_name":"批签发量","indicator_value":["66万瓶","15116","15120"],"indicator_element":{"时间":["2020Q4","15097","15103"],"产品":["凝血酶原复合物","15104","15111"]},"indicator_supplement":{"属性":""}}]},{"id":"125","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升171%","content_offset":["15121","15129"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["171%","15125","15129"],"indicator_element":{"时间":["2020Q4","15097","15103"],"产品":["凝血酶原复合物","15070","15077"]},"indicator_supplement":{"属性":""}}]},{"id":"126","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月，凝血酶原复合物批签发量为16万瓶","content_offset":["15130","15155"],"indicators":[{"indicator_name":"批签发量","indicator_value":["16万瓶","15151","15155"],"indicator_element":{"时间":["2020年12月","15130","15138"],"产品":["凝血酶原复合物","15139","15146"]},"indicator_supplement":{"属性":""}}]},{"id":"127","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比上升74%","content_offset":["15156","15163"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["74%","15160","15163"],"indicator_element":{"时间":["2020年12月","15130","15138"],"产品":["凝血酶原复合物","15070","15077"]},"indicator_supplement":{"属性":""}}]},{"id":"128","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"纤维蛋白原2008-2020年CAGR为+48.53%","content_offset":["16046","16073"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+48.53%","16066","16073"],"indicator_element":{"时间":["2008-2020年","16051","16061"],"产品":["纤维蛋白原","16046","16051"]},"indicator_supplement":{"属性":""}}]},{"id":"129","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年1-12月，纤维蛋白原批签发总量为125万瓶","content_offset":["16092","16119"],"indicators":[{"indicator_name":"批签发量","indicator_value":["125万瓶","16114","16119"],"indicator_element":{"时间":["2020年1-12月","16092","16102"],"产品":["纤维蛋白原","16103","16108"]},"indicator_supplement":{"属性":""}}]},{"id":"130","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长41%","content_offset":["16120","16127"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["41%","16124","16127"],"indicator_element":{"时间":["2020年1-12月","16092","16102"],"产品":["纤维蛋白原","16035","16040"]},"indicator_supplement":{"属性":""}}]},{"id":"131","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020Q4，纤维蛋白原批签发量为44万瓶","content_offset":["16128","16149"],"indicators":[{"indicator_name":"批签发量","indicator_value":["44万瓶","16145","16149"],"indicator_element":{"时间":["2020Q4","16128","16134"],"产品":["纤维蛋白原","16135","16140"]},"indicator_supplement":{"属性":""}}]},{"id":"132","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长128%","content_offset":["16150","16158"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["128%","16154","16158"],"indicator_element":{"时间":["2020Q4","16128","16134"],"产品":["纤维蛋白原","16103","16108"]},"indicator_supplement":{"属性":""}}]},{"id":"133","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"2020年12月，纤维蛋白原批签发量为7万瓶","content_offset":["16167","16189"],"indicators":[{"indicator_name":"批签发量","indicator_value":["7万瓶","16186","16189"],"indicator_element":{"时间":["2020年12月","16167","16175"],"产品":["纤维蛋白原","16176","16181"]},"indicator_supplement":{"属性":""}}]},{"id":"134","source_document":"2020年1-12月血制品批签发：Q4国产人白持续下滑.pdf","content":"同比增长19%","content_offset":["16190","16197"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["19%","16194","16197"],"indicator_element":{"时间":["2020年12月","16167","16175"],"产品":["纤维蛋白原","16103","16108"]},"indicator_supplement":{"属性":""}}]}]}